Navigation Links
Scientists develop mathematical model to predict the immune response to influenza
Date:5/13/2009

Researchers at the University of Rochester have developed a mathematical model to predict immune responses to infection with influenza A viruses, including novel viruses such as the emergent 2009 influenza A (H1N1). This model examines the contributions of specific sets of immune cells in fighting influenza A virus. The model also helps predict when during the immune response to viral infection antiviral therapy would be most effective.

The project was conducted by investigators funded through the Modeling Immunity for Biodefense program, a program established in 2005 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to improve preparedness for emerging and re-emerging pathogens.

When an individual is infected by a virus, a network of immune cells becomes immediately engaged, taking up viral particles and presenting pieces of the virusantigensto specialized white blood cells, thereby initiating a virus-specific response. The responding cells include T cellswhich either directly attack and eliminate virus-infected cells or help other immune cells fight the virusas well as B cells, which produce antibodies that bind and neutralize the virus.

The mathematical model developed by the research team generates immune response scenarios reflecting multiple variables, including the pathogenicity of the virus, numbers of responding B and T cells and function of antigen-presenting cells, in the lungs and lymph nodes. Their model suggests that prolonged viral infection limits the production of T cells and inhibits antigen presentation to immune cells. Confirming previous findings, the mathematical model predicts that antiviral therapy is most effective in reducing the spread of the virus when given within two days after infection.

The research team tested the accuracy of their model in mice infected with influenza A virus. They next plan to apply the model to human populat
'/>"/>

Contact: Julie Wu
wujuli@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 27, 2015 , ... In the addiction treatment industry, some patients go through ... and returning again, all at great cost to them and their families. Others have ... soon after leaving facilities who claim to have given addicts tools to overcome their ...
(Date:8/27/2015)... ... August 27, 2015 , ... In an article ... situation in the city of New Orleans, highlighting a security firm that is tasked ... by a tech oriented entrepreneur who worked with the city to provide private security ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... years after Hurricane Katrina slammed into the Gulf Coast, killing more than 1,800 ... $100 billion, according to a Georgia State University study. , While most people ...
(Date:8/27/2015)... ... 27, 2015 , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., ... Licensed to practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study ... also practices in Healthpointe’s La Mirada clinic and Garden Grove clinic. , ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... company and leading biopharmaceutical contract development manufacturing company (CDMO), announced today that it ... (“Hepalink”) for $205.68M in cash. , The addition of Cytovance Biologics ...
Breaking Medicine News(10 mins):Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4
... S-transferase T1 (GSTT1) null genotypes have been linked to ... association between GSTM1 and GSTT1 null genotypes and the ... majority of previous reports are limited by their small ... genotype with the risk of GC and CRC need ...
... Climate Conference in Copenhagen approaches its conclusion, negotiations are ... change. The new ,Reducing Emissions from Deforestation and Forest ... element of any new agreement. Since deforestation accounts ... new policy would enable developing countries to make a ...
... gender differences that explain the aging inequity , ... yet another gender inequity: Women develop more and deeper ... do. , The disadvantage had long been suspected, but ... Foad Nahai, a plastic surgeon practicing in Atlanta and ...
... - Procedure Provides Efficient Mechanism to Pursue Approval in ... - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) ... for its twice-daily tramadol-acetaminophen formulation in Europe under the ... that allows a company to simultaneously pursue regulatory approval ...
... LONDON, December 17 Researchers from the School of ... the UK are today,encouraging families worldwide to take more regular ... two-thirds of people,across the globe are not walking together as ... and Austrians (63%) most likely to,walk together. , ...
... ... natural relief prior to considering drugs. , ... St. Louis, MO (PRWEB) December 17, 2009 -- D-Psoria ... associated with severe skin conditions . Developed by Astrel Genome Ltd., D-Psoria ...
Cached Medicine News:Health News:Forests take center stage at Copenhagen 2Health News:Mouth Area Wrinkles More in Women Than Men 2Health News:Mouth Area Wrinkles More in Women Than Men 3Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4
(Date:8/27/2015)... VEGAS , Aug. 27, 2015 The nation,s ... in a Las Vegas courtroom.  Attorneys ... argue the men suffered severe effects, including death, after using ... our clients what they as a company knew, that their ... attorney Robert Eglet .  "In order to hold Takeda ...
(Date:8/27/2015)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced ... the use of ActiPatch®, its novel musculoskeletal pain therapy, ... of the European Pain Federation EFIC®, Vienna, ... Company will also be exhibiting at the Congress in ... department clinical and experimental rheumatology from the University of ...
(Date:8/27/2015)... HARRISBURG, Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular ... and second in the United States ... a new type of stent for blockages in the main ... flexibility within the artery and potentially less risk for stent ... MIMICS-2 is a prospective, single-arm, multicenter clinical trial of the ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2First Pennsylvania Patient Treated in Landmark Vascular Study 2
... MediSensors, Inc. ( www.c8medisensors.com ), the leader in developing ... today that it has filed for CE mark approval ... Europe. The monitor is currently an adjunct investigational device. ... "The European Union has over 30 million people with ...
... 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... Stock Exchange (the "NYSE") has notified the Company that it ... Company,s failure to timely file its Annual Report on Form ... Under NYSE rules, when a Company does not comply with ...
Cached Medicine Technology:C8 MediSensors Files for CE Mark Approval, Advancing Plans for 2012 Product Introduction In Europe 2American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... Consensus knee system continues the "Consensus Concept" ... with the diversified experience of a Scientific ... knee system that incorporates state-of-the-art features. Consensus ... joint and implant stability and allow near ...
Profix total knee system is intended for cemented use only....
Medicine Products: